Eric K. Singhi on BEAT-SC: Phase 3 Bev + Chemo/Atezo v Chemo/Atezo in 1L ES-SCLC
Eric K. Singhi shared the following on X:
“BEAT-SC: Phase 3 Bev + Chemo/Atezo v Chemo/Atezo in 1L ES-SCLC
- 333 pts from Japan & China
- mPFS 5.7 v 4.4 months (HR 0.70)
- mOS 13 v 16.6 (HR 1.22), immature
How does this compare to 1L IMpower133 findings and what about other SCLC targets?”
Source: Eric K. Singhi/X
Dr. Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
OncoDaily
Dr. Singhi is highly skilled in general internal medicine and hematology/oncology, with a special focus on thoracic medical oncology. Fluent in multiple languages, including Hindi and Spanish, he is dedicated to providing personalized care and improving patient outcomes. Dr. Singhi’s interests extend to patient education, patient-reported outcomes, and community outreach.
He is affiliated with various hospitals in the Houston area, including Harris Health Ben Taub General and LBJ Hospitals, and The University of Texas MD Anderson Cancer Center. With over 6-10 years of experience, Dr. Eric K. Singhi is committed to delivering exceptional care to his patients and advancing the field of oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023